Delivery Order SPE2DB24D2101-SPE2DB25FKNUF
- Not listed
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $23,123.28 on August 7, 2025, for the supply of AVEED 750 mg/3 mL vials. This firm fixed-price delivery order, which has an ultimate completion date of August 28, 2025, represents a competitive award with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order valued at $14,452.05 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of AVEED 750 mg/3 mL vials. The contract represents a firm fixed price delivery order with an ultimate completion date of August 20, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established capability to meet...
- The Defense Logistics Agency awarded a delivery order valued at $44,319.62 to AmerisourceBergen Drug Corp for AVEED 750 mg/3 mL vials on August 7, 2025, with completion targeted for August 28, 2025. This firm fixed-price delivery order, which was not set aside for small business, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's distribution center in...
- The Defense Logistics Agency awarded a $34,684.92 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of AVEED 750 MG/3 ML vials. The contract is competitively awarded with no set-aside designation and carries a firm fixed price structure with an ultimate completion date of September 5, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,452.05 to AmerisourceBergen Drug Corp for AVEED 750 mg/3 mL vials on August 21, 2025, with completion targeted for September 12, 2025. This firm fixed-price contract, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AVEED (testosterone undecanoate) is a long-acting testosterone replacement therapy indicated for treating hypogonadism in...
- The U.S. Defense Logistics Agency (DLA) awarded a $38,826.00 Firm Fixed Price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide AVEED 750 MG/3 ML VIAL 3ML prescription medication. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $35,300.50 firm fixed-price delivery order is for the supply of AVEED 750 MG/3 ML VIAL 3ML, a specialty medication. The contract has an ultimate completion date of August 16, 2022 and was awarded on July 26, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,926.94 firm fixed-price delivery order is for the medical product "AVEED 750 MG/3 ML VIAL 3ML" and has an ultimate completion date of March 19, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $77,652 firm fixed-price delivery order is for the supply of AVEED 750 MG/3 ML VIAL 3ML, a specialty pharmaceutical product. The contract has an ultimate completion date of September 3, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
- This federal contract award is a Delivery Order valued at $7,707.76 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of AVEED 750 MG/3 ML VIAL 3ML, a medical product, with a performance period ending on February 14, 2025. The contract is a Firm Fixed Price arrangement, and there is no set-aside designation indicated. AmerisourceBergen holds a significant Indefinite...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKNUFDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of AVEED 750 MG/3 ML vials. This competitive, firm fixed-price delivery order, valued at $2,890.41, was executed on August 22, 2025, with an ultimate completion date of September 15, 2025. The products will be performed and delivered from AmerisourceBergen's location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive pharmaceutical supply vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical federal vendor serving the Defense Health Agency and other government healthcare systems. The company's extensive portfolio includes brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The non-set-aside competitive award reflects AmerisourceBergen's demonstrated capability to meet federal medical procurement requirements. AVEED (testosterone undecanoate) is a pharmaceutical product typically used in hormone replacement therapy, underscoring the company's role in supplying specialized medical treatments to support military personnel and beneficiary healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 8/22/25 |